Scientific Advances and New Frontiers in Mesothelioma Therapeutics

Luciano Mutti, Tobias Peikert, Bruce W.S. Robinson, Arnaud Scherpereel, Anne S. Tsao, Marc de Perrot, Gavitt A. Woodard, David M. Jablons, Jacinta Wiens, Fred R. Hirsch, Haining Yang, Michele Carbone, Anish Thomas, Raffit Hassan

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.

Original languageEnglish (US)
Pages (from-to)1269-1283
Number of pages15
JournalJournal of Thoracic Oncology
Issue number9
StatePublished - Sep 2018


  • Biomarkers
  • Chemotherapy
  • Immunotherapy
  • Malignant pleural mesothelioma
  • Oncology therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Scientific Advances and New Frontiers in Mesothelioma Therapeutics'. Together they form a unique fingerprint.

Cite this